✦ LIBER ✦
O-151 Phase II study of anatumomab mafenatox (ABR-214936) in advanced NSCLC: Results of a multi-institutinal open label repeat dose trial with patient-specific dose escalation
✍ Scribed by Langer, Corey J.; Katherine Alpaugh, R.; Robert, Francisco; Weiner, L.M.; Schiller, Joan; Kopreski, M.; Rogatko, Andre; Forsberg, Goran
- Book ID
- 118571542
- Publisher
- Elsevier Science
- Year
- 2003
- Tongue
- English
- Weight
- 188 KB
- Volume
- 41
- Category
- Article
- ISSN
- 0169-5002
No coin nor oath required. For personal study only.